Back to search

National and Kapodistrian University of Athens

Μελέτη βιοδεικτών στο μη μικροκυτταρικό καρκίνο του πνεύμονα

Abstract

dc:description

Lung cancer is the leading cause of cancer death worldwide. Many patients have metastatic disease at diagnosis and prognosis is dismal with 21% 5-year overall survival for all stages. Recently, promising therapies have emerged based on PD-1/PD-L1 immune checkpoint inhibitors which have been approved even as frontline treatment for patients with non-small cell lung cancer (NSCLC). We examined the association between PD-L1 expression and clinicopathological parameters as well as overall survival in 220 NSCLC patients. PD-L1 expression using 22C3 PharmDx DAKO monoclonal antibody (mAb) was defined as high when tumour proportion score (TPS) was ≥50%, low if TPS was 1-49% and absent when TPS was <1%. EGFR mutations were detected by COBAS, while KRAS and BRAF by Pyrosequencing. ROS1 and ALK rearrangements were estimated by immunohistochemistry with positive cases being confirmed by CISH and FISH respectively. Finally, ERCC1 and RRM1 expression was estimated by immunohistochemistry. Data analysis was performed using SPSS v24.0. PD-L1 expression was positively correlated with KRAS mutations. Anti-PD-1 therapy (pembrolizumab) prolonged patients overall survival compared to any other treatment strategy. Interestingly, when pembrolizumab combined with the presence of KRAS mutations showed a statistically significant difference (p<0.001) in overall survival compared to absence of KRAS mutations. Moreover, when ERCC1 expression combined with the platinum-based chemotherapy, showed that patients with no ERCC1 expression had a statistically significant survival benefit (p<0.001). In multivariate analysis, PD-L1 status, stage and anti-PD1 treatment were independent variables for overall survival. Treatment with pembrolizumab prolongs overall survival while PD-L1 expression and advanced stage emerge as poor prognostic factors in NSCLC patients. KRAS mutations may affect tumour microenvironment and patient's response to immunotherapy. Immune checkpoint inhibitors could represent an alternative therapeutic option for KRAS mutant NSCLC patients. Further investigation into this notion is warranted in order to validate the abovementioned observation.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2020

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Karatrasoglou, Eleni
  • Καρατράσογλου, Ελένη

Subjects

dc:subject × 11

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/47105

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Karatrasoglou, Eleni; Καρατράσογλου, Ελένη. Μελέτη βιοδεικτών στο μη μικροκυτταρικό καρκίνο του πνεύμονα. National and Kapodistrian University of Athens, 2020. http://hdl.handle.net/10442/hedi/47105